Gland Pharma
Manufacturing · India · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
plot no. 11 & 84 Tsiic Phase Iv Pashamyl...Phone Number
+91 4030510999Website
www.glandpharma.comRevenue
$673.7 MillionStock Symbol
GLANDIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Gland Pharma
Gland Pharma Limited is a rapidly growing global manufacturer of generic injectables, supplying to markets including the United States, Europe, Canada, Australia, and India. The company specializes in complex injectables, oncology, and ophthalmics, leveraging its robust R&D and manufacturing capabilities. Established in 1978 in Hyderabad, India, Gland Pharma has expanded its operations to over 60 countries, focusing on a business-to-business model. With a commitment to high-quality and affordable products, Gland Pharma aims to meet diverse injectable needs across the pharmaceutical industry.Explore more
Gland Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Gland Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Gland Pharma has new funding data
Gland Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Gland Pharma
Check out if Gland Pharma is spiking on competitors!
Earning: See what the market has to say on Gland Pharma recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if Gland Pharma had a recent Job posting/layoffs
Product Launch: Get notified when Gland Pharma launches new products
Check if Gland Pharma has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Gland Pharma
Find 3 more new buyers
Explore company insights
Get a deeper look into Gland Pharma's structure, leadership, and market position:
Company Profile Activity
Activity Insights
Gland Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Gland Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Gland Pharma.
Gland Pharma financials insights
Gather financial insights about Gland Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Unspecified
$200M
Gland Pharma Tech Stack
A closer look at the technologies used by Gland Pharma
Most Recent Scoops
Facilities Relocation / Expansion
Gland Pharma has commenced execution of a recently announced INR 2,000 crore capital expenditure program, with Q1 FY27 capital expenditure amounting to INR 1,132 million directed toward capacity expansion, capability enhancement, and infrastructure additions. Ongoing projects including vial, ophthalmic, BFS line, and lyophilized product facilities at India sites, as well as a new block with vial and lyo capacity at Dundigal and a high-speed tool line at Fontenay under Cenexi, remain on track for completion by end of next year.
Facilities Relocation/Expansion, Spending/Investment, Capacity Planning, Manufacturing Operations
Facilities Relocation / Expansion
Gland Pharma is investing approximately INR 165 crore in an isolator line at its oncology plant, expected to be installed by January, as part of its broader capital expenditure program. Total capital expenditure for the current year is expected to be approximately INR 550 crore, with priority projects including Suite 10 in Pashamylaram featuring a new vial line, BFS, and ophthalmic line.
Facilities Relocation/Expansion, Spending/Investment, Manufacturing Operations
Partnership
Gland Pharma has entered a strategic collaboration with Neuland Laboratories to manufacture sterile APIs for microparticle depot products. This partnership strengthens Gland Pharma's capabilities in complex injectable technologies and supports its broader strategy of building differentiated, high-value product platforms.
Partnership
Facilities Relocation / Expansion
Gland Pharma has announced plans to discontinue one of the older ampoule lines at its Fontenay facility and replace it with a new high-capacity line as part of ongoing modernization efforts. The new line is expected to enter production in early 2027 and will add approximately 30 million ampoules of annual capacity.
Capacity Planning, Facilities Management, Manufacturing Operations
New Hire
Executive Move
Executive Moves, New Hire
Gland Pharma News & Media
Apotex Announces FDA Approval of Generic Infuvite® Pediatric Injection, Eligible for 180‑day CGT Exclusivity (Single‑Dose Vial), Complementing its Recent Approval of Generic Infuvite Adult Injection
WESTON, Fla., April 27, 2026 /PRNewswire/ - Apotex, in collaboration with Orbicular Pharmaceutical Technologies Pvt. Ltd. and Gland Pharma Limited, today announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for generic...Apotex Announces FDA Approval of First Generic Infuvite® Adult Injection (Single Dose Vial and Pharmacy Bulk package) with 180‑Day CGT Exclusivity for the Pharmacy bulk package in Partnership with Orbicular and Gland Pharma
WESTON, Fla., April 14, 2026 /PRNewswire/ - Apotex Corp., in partnership with Orbicular Pharmaceutical Technologies Pvt. Ltd. and Gland Pharma Limited, today announced that the U.S. Food and Drug Administration (FDA) has approved two Abbreviated New Drug Application (ANDA) for generic...Gland Pharma Shares Surge After Announcing Strong Q3FY26 Results
The Cenexi business segment also showed positive trends, with Q3 FY26 revenue reaching EURO 50 million, a 39 per cent increase year-on-year.Gland Pharma Announces Retirement of Chief Operating Officer Satnam Singh Loomba
Gland Pharma Limited has announced the retirement of Chief Operating Officer Mr. Satnam Singh Loomba, effective March 31, 2026, due to superannuation. Mr. Loomba, who joined the company on May 01, 2024, will also cease to be Senior Management Personnel from the retirement date. The Board of Directors has acknowledged his leadership and contributions during his tenure. The announcement was made in compliance with SEBI Regulation 30 requirements to both BSE and NSE exchanges.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Gland Pharma
Sign Up For FreeTo access detailed company insights
Gland Pharma Limited is a rapidly growing global manufacturer of generic injectables, supplying to markets including the United States, Europe, Canada, Australia, and India. The company specializes in complex injectables, oncology, and ophthalmics, leveraging its robust R&D and manufacturing capabilities. Established in 1978 in Hyderabad, India, Gl... Read More
